RARE vs. REMX

In the year-to-date period, RARE achieves a -16.54% return, which is significantly lower than REMX's -0.23% return. Over the past 10 years, RARE has underperformed REMX with an annualized return of -6.98%, while REMX has yielded a comparatively higher -3.77% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and VanEck Vectors Rare Earth/Strategic Metals ETF (REMX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RARE Sharpe Ratio is -0.34, which is higher than the REMX Sharpe Ratio of -0.78. The chart below compares the historical Sharpe Ratios of RARE and REMX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

RARE has not paid dividends to shareholders, while REMX's dividend yield for the trailing twelve months is around 2.56%.

The maximum RARE drawdown since its inception was -82.49%, smaller than the maximum REMX drawdown of -90.21%. Use the drawdown chart below to compare losses from any high point for RARE and REMX. For additional features, visit the drawdowns tool.